The primary agenda of the board meeting is to consider and approve the Unaudited Financial Results (both Standalone and Consolidated) of the Company for the half year ended September 30, 2026.
Additionally, the company has advised that pursuant to SEBI (Prohibition of Insider Trading) Regulations 2015, the trading window for dealing in the equity shares of the Company has been closed since October 01, 2026 and will remain closed until November 16, 2026. The trading window closure period encompasses the board meeting date and the subsequent period until financial results are formally disclosed.
This information has been disclosed to BSE Limited and is also available on the company's website at www.mahamayalifesciences.com.
The communication has been digitally signed by Kush Mishra, who holds the position of Company Secretary & Compliance Officer (Membership No. A62001) of Mahamaya Lifesciences Limited.